MAGL-IN-4
Modify Date: 2024-01-06 14:52:35
MAGL-IN-4 structure
|
Common Name | MAGL-IN-4 | ||
|---|---|---|---|---|
| CAS Number | 2135785-20-3 | Molecular Weight | 364.82 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C18H21ClN2O4 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of MAGL-IN-4MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain[1]. |
| Name | MAGL-IN-4 |
|---|
| Description | MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain[1]. |
|---|---|
| Related Catalog | |
| In Vitro | MAGL-IN-4 (compound 4f) shows a high LLE (5.9), a logD of 2.3 for MAGL[1]. MAGL-IN-4 exhibits no inhibition toward the closely related serine hydrolases (FAAH and ABHD6; all IC50>10000 nM). MAGL-IN-4 has no significant binding potentials to cannabinoid receptors (CB1: 19% and CB2: 5% at 10 μM), and low hERG liability (14.4% inh. at 10 μM, manual patch clamp, without BSA)[1]. |
| In Vivo | MAGL-IN-4 (compound 4f; 0.1-10 mg/kg; oral; single dose) results in a significant elevation in the level of 2-AG and reduction in that of arachidonic acid (AA) from 0.3 mg/kg in C57BL/6J mice[1]. |
| References |
| Molecular Formula | C18H21ClN2O4 |
|---|---|
| Molecular Weight | 364.82 |